New Search

If you are not happy with the results below please do another search

2034 search results for:

264

Neuroscientists show how visual information travels from the retina to the midbrain

For the first time, neuroscientists from Charité – Universitätsmedizin Berlin and the Max Planck Institute for Biological Intelligence (currently in the process of being established) have revealed the precise connections between sensory neurons inside the retina and the superior colliculus, a structure in the midbrain. Neuropixels probes are a relatively recent development, representing the next […]

266

Avacta’s AVA6000 receives Orphan Drug Designation from US FDA

Avacta Group, a clinical stage oncology drug company and developer of diagnostics based on its innovative Affimer and pre|CISION platforms, has been granted Orphan Drug Designation (ODD) by the US FDA of the company’s lead pre|CISION drug candidate, AVA6000, for treatment of soft tissue sarcoma.

267

Beckman Coulter installs the world’s 100th DxA Automation System

San Paolo Hospital in Savona, Italy, has upgraded its Corelab-related analytical equipment. In collaboration with Beckman Coulter, the San Paolo diagnostic laboratory has installed Beckman Coulter’s DxA 5000 Laboratory Automation System, an innovative, high-throughput automation system that rapidly increases test processing. This latest installation of Beckman Coulter’s DxA Automation System marks the 100th installation worldwide […]

268

New study recommends switch to volumetric DBS sampling devices to ensure accuracy of PKU monitoring

Swedish medtech start-up Capitainer says its qDBS card has scored highly in a major new study published in Clinica Chimica Acta on the advantages of volumetric microsampling DBS devices in monitoring of patients with phenylketonuria (PKU). The study was necessary according to the authors, because although measurement of dried blood spot phenylalanine (Phe) is central […]

269

EpiEndo commences LPS Challenge Trial for lead candidate EP395

EpiEndo Pharmaceuticals, a clinical-stage biopharmaceutical company developing disease-modifying therapeutics for chronic respiratory disorders, has received regulatory and ethics approval to commence a Lipopolysaccharide (LPS) challenge clinical trial with lead molecule EP395. EP395 is an orally available macrolide or ‘Barriolide’ with reduced antimicrobial activity which aims to address the unmet medical need for a treatment for […]

270

Lifespin launches commercial access to its metabolic profiler software and database for pharma and biobank services

Lifespin, based in Regensburg, Germany, with offices in Boston, Massachusetts, has launched a new commercial service that, for the first time, will provide the pharma­ceutical and biobanking industry with access to its proprietary metabolic database, as well as its advanced interpretive software to assist in various phases of drug research, development, and manufacturing.